clinical trial · NCT07042100
A Study to Test the Safety and Tolerability of SBO-154 in Patients With Advanced Solid Tumors.
Advanced Solid TumorsDose level (DL)1DL2DL3DL4DL5
brief summary
This is a Phase 1 study of SBO-154 in patients with advanced cancers who are unable to tolerate or have not previously responded to standard therapy available in the country. The study involves multiple doses and takes place at several centers.
started
Aug 12, 2025
primary completion
Aug 1, 2028
completion
Aug 1, 2030
last updated
Jun 3, 2026
detailed description
This study has two parts. In Part 1, the goal to evaluate the safety and tolerability along with the highest dose that can be tolerated, or the dose(s) which can be chosen for further evaluation. In Part 2, the focus is on evaluating the safety of SBO-154 in specific types of advanced cancers.
official title
A Phase 1, Multicentre, Open-label, Multiple-dose Study to Determine Safety, Tolerability, and Preliminary Efficacy of SBO-154 in Subjects With Advanced Solid Tumors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol